needle-1291170_960_720

Genentech shares results from phase 3 trial for MS treatment

July 13, 2023
Research and Development Genentech, MS, Neurology, Ocrevus, clinical trial

Genentech has announced positive results from its phase 3 OCARINA II trial which assessed Ocrevus (ocrelizumab) as a twice-a-year, ten-minute …

CellCentric announces $25m investment from Pfizer

July 12, 2023
Business Services Cancer, CellCentric, Oncology, Pfizer, collaboration, investment

UK-based biotechnology company CellCentric has announced a strategic investment from Pfizer including $25m to finance further development of inobrodib, its …

ADC Therapeutics puts clinical trial enrollment on hold following patient deaths

July 12, 2023
Medical Communications ADC Therapeutics, DLBCL, Oncology, clinical trial

ADC Therapeutics has announced a voluntary pause in the enrollment of patients for its phase 2 LOTIS-9 clinical trial which …

Virtual Inspections: Embracing the Digital Change

July 12, 2023
Manufacturing and Production ACG, Pharmacy, digital, manufacturing, virtual inspections

Virtual inspections must become a part of companies’ repertoires if they aim to maintain quality standards in their organisations. Digital …

Innate Pharma doses first patient in relapsed/refractory multiple myeloma trial

July 11, 2023
Research and Development Innate Pharma, Oncology, Sanofi, clinical trial, multiple myeloma

Innate Pharma has announced that the first patient has been dosed in its Sanofi-sponsored phase 1/2 clinical trial, which aims …

eye2

Astellas and 4D Molecular Therapeutics enter license agreement for rare ophthalmic targets

July 11, 2023
Research and Development 4D Molecular Therapeutics, AAV vectors, Astellas Pharma, Opthalmology, ophthalmology

Astellas Pharma and 4D Molecular Therapeutics (4DMT) have announced a license agreement under which Astellas has the right to use …

markus-spiske-dnbtfbnqlrc-unsplash_1

MHRA authorises GSKโ€™s RSV vaccine for older adults

July 10, 2023
Medical Communications Arexvy, GSK, Infections and infestations, MHRA, RSV

GSK has announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has authorised its Arexvy respiratory syncytial virus (RSV) …

Nanobiotix announces license agreement with Janssen for development and commercialisation of new cancer treatment

July 10, 2023
Sales and Marketing Cancer, Janssen, License Agreement, Oncology, nanobiotix

Nanobiotix has announced a global licensing, co-development and commercialisation agreement with Janssen Pharmaceutica NV, one of the Janssen Pharmaceutical Companies …

180921-drugs-pills-bottle-faeture-image

Celltrion launches Humira biosimilar in US

July 7, 2023
Medical Communications Chronic Diseases, Humira, Yuflyma, arthritis, celltrion

South Korean biopharmaceutical company Celltrion has announced that its US branch โ€“ Celltrion USA โ€“ has launched a Humira (adalimumab) …

Alzheimer's brain

FDA grants Alzheimerโ€™s disease drug Leqembi full approval

July 7, 2023
Medical Communications Alzheimer's disease, Biogen, Eisai, FDA, Neurology

Japanese pharmaceutical company Eisai and US-based biotechnology company Biogen have announced that the US Food and Drug Administration (FDA) has …

OSE Immunotherapiesโ€™ UC drug gets DSMB positive recommendation

July 6, 2023
Research and Development EMA, Gastrointestinal tract, OSE Immunotherapeutics, ulcerative colitis

Frenchย biotech company OSE Immunotherapeutics has announced that its Ulcerative Colitis (UC) trialโ€™s Independent Drug Safety Monitoring Board (DSMB) has provided …

FDA grants Priority Review for Astellas Pharmaโ€™s BLA for cancer drug

July 6, 2023
Research and Development Astellas Pharma, Biologics License Application, FDA, GEJ, Oncology

Japanese pharmaceutical company Astellas Pharma has announced that the US Food and Drug Administration (FDA) has granted Priority Review for …

Skyline Therapeutics receives FDA clearance of IND for candidate for neovascular age-related macular degeneration

July 5, 2023
Research and Development FDA, IND, Opthalmology, Skyline Therapeutics, neovascular age-related macular degeneration

Skyline Therapeutics has announced that the US Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application …

Jacobio Pharma receives CDE approval for pancreatic cancer study in China

July 5, 2023
Medical Communications CDE, China, Jacobio Pharma, Oncology, Pancreatic cancer, clinical trial

Jacobio Pharma has announced that its novel KRAS G12C inhibitor glecirasibโ€™s pivotal study for pancreatic cancer has been approved by …

Roger Dmochowski appointed as Versamebโ€™s chief medical officer

July 5, 2023
Business Services Roger Dmochowski, Urology, Versameb, appointment, chief medical officer

Versameb AB has announced the appointment of Professor Roger Dmochowski as chief medical officer. Dmochowski is a renowned researcher and …

Cytovation appoints Olav Hellebรธ to board of directors

July 5, 2023
Business Services Cytovation, Olav Hellebรธ, Oncology, appointment, board of directors

Cytovation ASA, a clinical stage immune-oncology company with a focus on targeted tumour membrane immunotherapies, has announced that it has …

Amsterdam UMCโ€™s new drug doubles remission rates in patients with ulcerative colitis

July 4, 2023
Research and Development Amsterdam UMC, Gastrointestinal tract, mirikizumab, ulcerative colitis

A new drug, being investigated by Amsterdam UMC along with colleagues at various universities, has been shown to be effective …

Croda International acquires Solus Biotech

July 4, 2023
Business Services Croda International, Pharmacy, Solus Biotech, acquisition

Croda International has confirmed that it has successfully acquired Solus Biotech, following receipt of approval from the South Korean regulatory …

brainss

Sosei Heptares announces first subject dosed in phase 1 trial for schizophrenia therapy

July 3, 2023
Research and Development HTL'149, Neurology, Sosei Heptares, clinical trial, schizophrenia

Sosei Heptares has announced that it has dosed its first patient in its phase 1 trial evaluating HTL0048149 (HTLโ€™149), a …

lungs

AstraZeneca shares results from phase 3 trial of datopotamab deruxtecan for NSCLC

July 3, 2023
Medical Communications AstraZeneca, NSCLC, Oncology, clinical trial, datopotamab deruxtecan

AstraZeneca has announced results from its TROPION-Lung01 phase 3 trial for its TROP2-directed antibody drug conjugate, developed in collaboration with …

The Gateway to Local Adoption Series

Latest content